.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Fish and Richardson
Argus Health
Deloitte
Mallinckrodt
Baxter
Cipla
Johnson and Johnson
Queensland Health
US Army

Generated: July 22, 2017

DrugPatentWatch Database Preview

Flibanserin - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for flibanserin and what is the scope of flibanserin freedom to operate?

Flibanserin
is the generic ingredient in one branded drug marketed by Sprout Pharms and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Flibanserin has seventy-four patent family members in thirty-one countries.

One supplier is listed for this compound.

Summary for Generic Name: flibanserin

Tradenames:1
Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list24
Clinical Trials: see list16
Patent Applications: see list363
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:flibanserin at DailyMed

Pharmacology for Ingredient: flibanserin

Mechanism of ActionP-Glycoprotein Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sprout Pharms
ADDYI
flibanserin
TABLET;ORAL022526-001Aug 18, 2015RXYesYes8,227,471► Subscribe ► Subscribe
Sprout Pharms
ADDYI
flibanserin
TABLET;ORAL022526-001Aug 18, 2015RXYesYes9,468,639► Subscribe ► Subscribe
Sprout Pharms
ADDYI
flibanserin
TABLET;ORAL022526-001Aug 18, 2015RXYesYes7,151,103► Subscribe ► Subscribe
Sprout Pharms
ADDYI
flibanserin
TABLET;ORAL022526-001Aug 18, 2015RXYesYes7,420,057► SubscribeYY ► Subscribe
Sprout Pharms
ADDYI
flibanserin
TABLET;ORAL022526-001Aug 18, 2015RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: flibanserin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,183,410Stable polymorph of flibanserin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: flibanserin

Country Document Number Estimated Expiration
MexicoPA04003666► Subscribe
Ukraine78974► Subscribe
Brazil0211601► Subscribe
Argentina077480► Subscribe
South Korea20040023704► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Chubb
Medtronic
Merck
Teva
Citi
Colorcon
Boehringer Ingelheim
Daiichi Sankyo
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot